Close Menu
Nabka News
  • Home
  • News
  • Business
  • China
  • India
  • Pakistan
  • Political
  • Tech
  • Trend
  • USA
  • Sports

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Williamson still wants to play for NZ, says coach – Sport

July 10, 2025

Seed technology drives cotton mechanization in China’s Xinjiang-Xinhua

July 10, 2025

US imposes sanctions on UN’s Francesca Albanese over Israel’s criticism

July 10, 2025
Facebook X (Twitter) Instagram
  • Home
  • About NabkaNews
  • Advertise with NabkaNews
  • DMCA Policy
  • Privacy Policy
  • Terms of Use
  • Contact us
Facebook X (Twitter) Instagram Pinterest Vimeo
Nabka News
  • Home
  • News
  • Business
  • China
  • India
  • Pakistan
  • Political
  • Tech
  • Trend
  • USA
  • Sports
Nabka News
Home » Hims & Hers offers generic semaglutide as Novo Nordisk patent lapses
Business

Hims & Hers offers generic semaglutide as Novo Nordisk patent lapses

i2wtcBy i2wtcJuly 9, 2025No Comments4 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email WhatsApp Copy Link
Follow Us
Google News Flipboard Threads
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025.

Gabby Jones | Bloomberg | Getty Images

Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January.

“Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers, in a press release. “As generic semaglutide becomes available for the first time globally, we’re focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.” 

Hims, a telehealth platform, joins a growing list of drugmakers that are looking to cash in on Novo Nordisk’s lapsed patent on its GLP-1s. It’s the first time the company will be operating in Canada.

Generics are essentially copies of a brand-name drug, like Ozempic or Wegovy, that deliver the same efficacy, follow the same safety standards and are allowed once a patent expires. These drugs are different from compounded versions of medications, which are personalized treatments that are changed in form or provided in different dosing levels than commercially available doses.

The Canadian semaglutide market in 2024 generated revenue of $1.18 billion and is expected to reach $4.03 billion by 2035, according to market research firm Grand View Research.

There is still no generic version of semaglutide on the market that’s been approved by the Canadian health agency, but the approval process has begun for some in the industry.

Sandoz, a global leader in generic medicine manufacturing, told Science in early June that it filed for approval of a generic version of semaglutide with Canada’s regulatory agency Health Canada. Hims did not say in its announcement if it has started a similar application for review, but did note it’s working with “an approved partner” to ensure it’s following all local laws and regulations.

More CNBC health coverage

Some in the industry have raised concerns about Novo letting its patent lapse, and it comes as Wegovy has lost ground to Eli Lilly‘s rival treatment, Zepbound, in the U.S. But a spokesperson for the company told CNBC that all intellectual property decisions are “carefully considered,” adding that “periods of exclusivity for pharmaceutical products end as part of their normal life cycle and generic treatments may become available over time.”

This announcement by Hims follows the closing of the company’s recent acquisition of European telehealth platform Zava, which expands the health platform in Europe to Ireland, France and Germany.

This also comes after Novo Nordisk ended its collaboration with Hims & Hers, citing concerns about the company’s sales and promotion of cheaper knockoffs of its weight loss drug Wegovy.

How Novo lost its Canadian patent

According to documents filed with the Canadian Patent Database, Novo held a patent for semaglutide, but the last time the company paid the annual maintenance fee was in 2018.

Novo Nordisk’s lawyers requested a refund for the paid 2017 maintenance fee of $250 Canadian dollars ($185) because the company wanted more time to see if it wanted to pay it, according to letters included in the documents.

Two years later, the office sent a letter saying the fee, which now included a late charge bringing the total to CA$450, was not received by the prescribed due date.

Novo Nordisk had a one-year grace period to pay, but never did, and so its patent lapsed in Canada. It lapsed in 2020 when the fee was not received, but it doesn’t expire until January.

Canadian authorities confirmed in their correspondence that “once a patent has lapsed it cannot be revived.”

“Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives,” said David Meinertz, general manager of the international business at Hims & Hers.

Don’t miss these insights from CNBC PRO



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email WhatsApp Copy Link
i2wtc
  • Website

Related Posts

Business

WK Kellogg shares jump 40% on Ferrero deal report

July 10, 2025
Business

Eli Manning not interested in ownership bid

July 9, 2025
Business

TSA plans to let travelers keep their shoes on at airport security

July 8, 2025
Business

Trump threatens pharmaceutical tariffs of 200%

July 8, 2025
Business

Boeing delivers most airplanes since late 2023 as 737 Max output rises

July 8, 2025
Business

Wendy’s CEO Kirk Tanner tapped to lead Hershey

July 8, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Williamson still wants to play for NZ, says coach – Sport

July 10, 2025

House Republicans unveil aid bill for Israel, Ukraine ahead of weekend House vote

April 17, 2024

Prime Minister Johnson presses forward with Ukraine aid bill despite pressure from hardliners

April 17, 2024

Justin Verlander makes season debut against Nationals

April 17, 2024
Don't Miss

Trump says China’s Xi ‘hard to make a deal with’ amid trade dispute | Donald Trump News

By i2wtcJune 4, 20250

Growing strains in US-China relations over implementation of agreement to roll back tariffs and trade…

Donald Trump’s 50% steel and aluminium tariffs take effect | Business and Economy News

June 4, 2025

The Take: Why is Trump cracking down on Chinese students? | Education News

June 4, 2025

Chinese couple charged with smuggling toxic fungus into US | Science and Technology News

June 4, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

About Us
About Us

Welcome to NabkaNews, your go-to source for the latest updates and insights on technology, business, and news from around the world, with a focus on the USA, Pakistan, and India.

At NabkaNews, we understand the importance of staying informed in today’s fast-paced world. Our mission is to provide you with accurate, relevant, and engaging content that keeps you up-to-date with the latest developments in technology, business trends, and news events.

Facebook X (Twitter) Pinterest YouTube WhatsApp
Our Picks

Williamson still wants to play for NZ, says coach – Sport

July 10, 2025

Seed technology drives cotton mechanization in China’s Xinjiang-Xinhua

July 10, 2025

US imposes sanctions on UN’s Francesca Albanese over Israel’s criticism

July 10, 2025
Most Popular

‘Where do we go?’: China Hat Road construction postponed for now, homeless still worried about future

July 29, 2024

China to launch three ancient astronauts to Tiangong Space Station – Spaceflight Now

October 29, 2024

EU investment in China surges to $3.9 billion, new quarterly record

October 31, 2024
© 2025 nabkanews. Designed by nabkanews.
  • Home
  • About NabkaNews
  • Advertise with NabkaNews
  • DMCA Policy
  • Privacy Policy
  • Terms of Use
  • Contact us

Type above and press Enter to search. Press Esc to cancel.